RT Journal Article
SR Electronic
T1 Vinorelbine and Cisplatin in Advanced Squamous Cell Carcinoma of the Cervix: The South African Experience
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2489
OP 2492
VO 25
IS 3C
A1 LOUIS GOEDHALS
A1 GEOFFREY FALKSON
A1 BRENDA LYNN SMITH
A1 CARLA ISADORA FALKSON
A1 JAMAL GASMI
A1 ANDRIES LATEGAN
A1 JEAN-PHILIPPE BURILLON
A1 PATRICIA HIS
YR 2005
UL http://ar.iiarjournals.org/content/25/3C/2489.abstract
AB Background: This phase II trial was performed to assess the activity and safety of the cisplatin and vinorelbine combination in patients with advanced cervical carcinoma. Patients and Methods: Forty-two patients with advanced cervical cancer were included in the study to receive vinorelbine at 30 mg/m2 on d 1 and d 8 and cisplatin 100 mg/m2 on day 1 every 4 weeks. Results: Thirty-seven patients were evaluable for response and 40 patients for tolerance. Twenty-four patients (64.8%) achieved objective responses. The median duration of response was 17.5 months (range 2.5-57 months), median time to progression was 13.2 months (range 0.4-57 months) and median survival was 20.6 months (range 0.4-55 months). This regimen was well-tolerated; no WHO grade 4 neutropenia was observed, grade 3 nausea and vomiting occured in 50% of patients and grade 2 peripheral neuropathy in 5% of patients. Conclusion: Vinorelbine-cisplatin is an active and well-tolerated regimen in advanced cervical carcinoma.